Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)”

50 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 50 results

Large-scale testing (Phase 3)Active Not RecruitingNCT04919226
What this trial is testing

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Who this might be right for
Neuroendocrine Tumors
ITM Solucin GmbH 259
Not applicableStudy completedNCT03017690
What this trial is testing

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Ipsen 22
Very early researchLooking for participantsNCT05359146
What this trial is testing

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

Who this might be right for
Neuroendocrine Neoplasia's (NENs)Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
University Hospital, Basel, Switzerland 16
Not applicableLooking for participantsNCT07302100
What this trial is testing

Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University Hospital

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
University Hospital, Strasbourg, France 100
Not applicableStudy completedNCT02948946
What this trial is testing

Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorLung Neuroendocrine Neoplasm
H. Lee Moffitt Cancer Center and Research Institute 105
Not applicableStudy completedNCT06853457
What this trial is testing

A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases

Who this might be right for
Neuroendocrine Tumors, NET
First Affiliated Hospital, Sun Yat-Sen University 257
Large-scale testing (Phase 3)Study completedNCT04852679
What this trial is testing

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Ipsen 43
Testing effectiveness (Phase 2)Ended earlyNCT03042780
What this trial is testing

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Who this might be right for
Gastro-enteropancreatic Neuroendocrine TumorPancreatic CancerNeuroendocrine Carcinomas of Pancreas+1 more
H. Lee Moffitt Cancer Center and Research Institute 2
Not applicableLooking for participantsNCT06402695
What this trial is testing

Observational Study on GEP-and Pulm-NET Treated at FPG

Who this might be right for
Neuroendocrine TumorsGep NetPulmonary Neuroendocrine Neoplasm
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 650
Testing effectiveness (Phase 2)Looking for participantsNCT04837885
What this trial is testing

Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases

Who this might be right for
Neuroendocrine TumorLiver MetastasesNeuroendocrine Gastroenteropancreatic Tumour
University Hospital, Bordeaux 23
Early research (Phase 1)Study completedNCT01263353
What this trial is testing

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Novartis Pharmaceuticals 36
Testing effectiveness (Phase 2)Study completedNCT02611024
What this trial is testing

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Who this might be right for
Advanced Solid TumorsGlioblastomaSoft Tissue Sarcoma (Excluding GIST)+9 more
PharmaMar 316
Post-approval studies (Phase 4)Study completedNCT04524442
What this trial is testing

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Advanced Accelerator Applications 42
Early research (Phase 1)Active Not RecruitingNCT05262556
What this trial is testing

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine NeoplasmNeuroendocrine Carcinoma+1 more
Amr Mohamed MD 15
Post-approval studies (Phase 4)Looking for participantsNCT05701241
What this trial is testing

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
University Hospital, Antwerp 270
Early research (Phase 1)Looking for participantsNCT04609592
What this trial is testing

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Stanford University 10
Testing effectiveness (Phase 2)Looking for participantsNCT05773274
What this trial is testing

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Who this might be right for
Metastatic Digestive System Neuroendocrine Tumor G1Metastatic Digestive System Neuroendocrine Tumor G2Unresectable Digestive System Neuroendocrine Tumor G1+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT03980925
What this trial is testing

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Who this might be right for
Neuroendocrine TumorsNeuroendocrine NeoplasmGastroenteropancreatic Neuroendocrine Tumor
Grupo Espanol de Tumores Neuroendocrinos 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT04711135
What this trial is testing

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorsPheochromocytomaParaganglioma
Advanced Accelerator Applications 11
Not applicableStudy completedNCT04986085
What this trial is testing

Nutrition in Gastroenteropancreatic Neuroendocrine Tumor

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Grupo Espanol de Tumores Neuroendocrinos 399
Load More Results
100